Back

Abbott Laboratories

Case Details

Class Period: February 19, 2021 - June 8, 2022
Date Filed: August 31, 2022
Case Number: 1:22cv04661
Jurisdiction: Illinois Northern District Court
icon-casetype Case Type: Securities Case
Days Left to
Seek Plaintiff:
36

Case Summary

The complaint alleges that, throughout the Class Period, Defendants made numerous materially false and misleading statements and omissions concerning what the U.S. Food and Drug Administration (“FDA”) called “egregiously unsanitary” conditions at the Company’s Sturgis facility. Specifically, Defendants repeatedly touted to investors the safety and salability of Abbott Laboratories’ infant formula brands and their contribution to the Company’s sales and revenue growth. In truth, Abbott’s Sturgis facility was in flagrant violation of multiple federal and state health and safety regulations. Those violations, which Defendants willfully or recklessly concealed from investors, put Abbott’s infant formula business in dire jeopardy and left the Company exposed to a risk of severe regulatory action, including the recall of its products and closure of the Sturgis facility. By no later than February 2021 and continuing throughout the Class Period, Abbott and Defendants received direct warnings, communications, FDA inspection reports, and consumer complaints identifying in detail the safety and regulatory violations that were rampant at the Sturgis facility. As a result of Defendants’ misrepresentations and omissions, Abbott common stock traded at artificially inflated prices during the Class Period. The truth began to emerge on February 17, 2022, when the FDA publicly announced that it was investigating four consumer complaints of infant illness related to powdered infant formula produced by Abbott in Sturgis. The FDA stated that it had initiated an onsite inspection at the facility, and to date had found several positive contamination results from environmental samples for a bacteria, Cronobacter sakazakii (“Cronobacter”), linked to infant illnesses and death. The FDA also revealed that its review of Abbott’s internal records indicated “environmental contamination with Cronobacter and the firm’s destruction of product due to the presence of Cronobacter.” As a result of these disclosures, the price of Abbott stock declined $3.79 per share, or 3.14%. In the following days, Abbott was forced to close the Sturgis plant due to the severe safety problems, shuttering one of the major sources of infant formula for the entire United States, as well as certain Canadian and foreign markets. Approximately one month later, on March 22, 2022, the FDA released reports from its three inspections of the Sturgis facility conducted from 2019 through 2022. Those reports indicated that (a) Abbott failed to establish process controls “designed to ensure that infant formula does not become adulterated due to the presence of microorganisms in the formula or in the processing environment” and (b) Abbott failed to “ensure that all surfaces that contacted infant formula were maintained to protect infant formula from being contaminated by any source.” On the news of these damaging inspection reports, the price of Abbott stock declined $4.97 per share, or 4%. As the FDA investigation continued, a redacted copy of a whistleblower complaint sent to the FDA in October 2021 was made public on April 22, 2022. Among other things, the whistleblower complaint revealed that the issues disclosed in February and March 2022 were actually known to Abbott’s management far earlier. Upon release of the whistleblower complaint, the price of Abbott stock declined $4.51 per share, or 3.8%. Then, on June 8, 2022, investors learned that, contrary to the Company’s repeated denials, Abbott was aware of the whistleblower’s formal allegations in early 2021, when it was reported that the FDA whistleblower had filed a complaint in February 2021 with the U.S. Labor Department’s Occupational Safety & Health Administration (“OSHA”), and that OSHA delivered that complaint to Abbott and the FDA during the same month. In response, the price of Abbott stock declined $4.17 per share, or 3.5%.

Documents
Complaint